- Inicio
- Análisis gratuito de aplicaciones
- MediMama: Zwanger-Medicijnen
- MediMama: Zwanger-Medicijnen Vs. PRN Graph
MediMama: Zwanger-Medicijnen vs PRN Graph Uso & Estadísticas
The MediMama app enables easy and quick access to information on safety of over-the-counter medicines during pregnancy and breastfeeding.
MediMama was developed by Moeders van Morgen, part of the Netherlands Pharmacovigilance Centre Lareb. Moeders van Morgen Lareb is the knowledge centre on medicine use during conception, pregnancy and breastfeeding.
In the MediMama app, you can search easily and quickly whether or not you can use an over-the counter-medicine during pregnancy or breastfeeding.
- You will immediately see whether you can use the medicine;
- You can look for safe alternatives to a medicine;
- You can look up hundreds of medicines in the app.
The MediMama app allows searching for a specific medicine or a brand, but also for a group of medicines. The app also provides life style advice that may help in reducing pregnancy related complaints before you start taking medication. Always consult your doctor or midwife for personal advice in case of persistent complaints or when you are worried.
- App Store de Apple
- Gratis
- Medicina
Clasificación de tiendas
- -
Perined is a joint effort of five organisations of professionals involved in perinatal care in the Netherlands: midwives, general practitioners, gynaecologists, paediatricians and pathologists. Main activities are perinatal registry and perinatal audit in the Netherlands, focused on the improvement of perinatal care. Nearly all childbirths at home as well as in a clinical setting are registered in the perinatal registry of Perined. See for more information: www.perined.nl .
The charts were derived from data on Dutch infants who were born and registered in the perinatal database of Perined, between 2000 and 2014. In contrast to the 2008 PRN/Perined birth weight charts, all infants with risk factors for deviant fetal growth were excluded. Among the excluded records were mothers with hypertensive disorders, diabetes or other medical conditions, substance-abusing mothers, pregnancies complicated by placental abnormalities or intrauterine infections, multiple gestations, and infants with congenital malformations. Infants born after induction of labor or elective caesarean section were also excluded. The remaining low-risk population (n=1.629.776) served as the reference population for the new birth weight charts, which intend to reflect the optimal birth weight of infants born at the corresponding gestational age. The charts are stratified by gender; because of different risk profiles the charts are no longer stratified by parity and Hindustani ethnicity, in contrast to the former PRN/Perined-charts.
These birth weight charts are developed by Liset Hoftiezer, supported by a taskforce with the following members (in alphabetical order): Joyce Dijs-Elsinga, Jeroen van Dillen, Michel Hof, Marije Hogeveen, Chantal Hukkelhoven, Karline van de Kamp, Richard van Lingen, Alieke de Roon-Immerzeel, Rosalinde Snijders, Viki Verfaille, Ger de Winter en Koos Zwinderman.
The birth weight charts were developed with financial support from the Isala Innovation and Science fund as well as Nutricia Early Life Nutrition. The financial contribution concerned the researchers place. There has been no interference with the content or findings of the project.
© 2017 Perined
- App Store de Apple
- Gratis
- Medicina
Clasificación de tiendas
- -
MediMama: Zwanger-Medicijnen frente a PRN Graph: comparación de la clasificación
Comparar la tendencia de clasificación de MediMama: Zwanger-Medicijnen en los últimos 28 días con PRN Graph
Rank
No hay datos disponibles
Comparación de las clasificaciones MediMama: Zwanger-Medicijnen frente a PRN Graph por países
Comparar la tendencia de clasificación de MediMama: Zwanger-Medicijnen en los últimos 28 días con PRN Graph
Todas las categorías
No hay datos disponibles
Medicina
Compara con cualquier sitio gracias a nuestra prueba gratuita
MediMama: Zwanger-Medicijnen VS.
PRN Graph
enero 10, 2025